Effect of Ranibizumab on Malignant Conjunctival Neoplasia
Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety and tolerability of subconjunctival injection
of ranibizumab in the treatment of malignant conjunctival neoplasia using the incidence and
severity of adverse events.
Our secondary objective is to assess the efficacy of ranibizumab treatment on malignant
conjunctival neoplasia by evaluating tumor destruction or reduction as documented by
slit-lamp photography and ultrasonographic imaging and the regression of blood vessels.